Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study.

BMC Pulm Med · 2026 · PMC12990618 · PMID 41668000

Europe PMC DOI

hedged sentence

0.1750

closest p · 3.5× alpha

0.1750

boldest claim

The sentences

did not reach statistical significancep = 0.175not close (p > 0.1)

As for lung function, 64.7% of patients in the mepolizumab group and 80.7% in the benralizumab group had stable or improved FEV1, although this difference did not reach statistical significance ( p = 0.175) (Fig. 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.